Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions - PubMed (original) (raw)
Review
Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions
Chien-Chung Chang et al. Adv Cancer Res. 2005.
Abstract
Changes in classical and nonclassical HLA class I antigen and NK cell-activating ligand expression have been identified in malignant lesions. These changes, which are described in this chapter, are believed to play a major role in the clinical course of the disease since both HLA class I antigens and NK cell-activating ligands are critical to the interaction between tumor cells and components of both innate and adaptive immune systems. Nevertheless, there is still debate in the literature about the biologic and functional significance of HLA class I antigen and NK cell-activating ligand abnormalities in malignant lesions. The reasons for this debate are reviewed. They include (i) the incomplete association between classical HLA class I antigen changes and the clinical course of the disease; (ii) the relatively limited number of malignant lesions that have been analyzed for nonclassical HLA class I antigen and NK cell-activating ligand expression; and (iii) the conflicting data regarding the role of immunoselection in the generation of malignant cells with HLA antigen and NK cell-activating ligand abnormalities. The technical limitations associated with the assessment of HLA antigen and NK cell-activating ligand expression in malignant lesions as well as the immunological and nonimmunological variables that may confound the impact of HLA antigen and NK cell-activating ligand changes on the clinical course of the disease are also discussed. Future studies aimed at overcoming these limitations and characterizing these variables are expected to provide a solution to the current debate regarding the significance of HLA class I antigen and NK cell-activating ligand abnormalities in malignant lesions.
Similar articles
- NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance.
Chang CC, Ferrone S. Chang CC, et al. Semin Cancer Biol. 2006 Oct;16(5):383-92. doi: 10.1016/j.semcancer.2006.07.001. Epub 2006 Jul 7. Semin Cancer Biol. 2006. PMID: 16931041 Review. - Association of HLA class I and class II antigen expression and mortality in uveal melanoma.
Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Ericsson C, et al. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2153-6. Invest Ophthalmol Vis Sci. 2001. PMID: 11527924 - Tumor cell recognition by natural killer cells.
Long EO. Long EO. Semin Cancer Biol. 2002 Feb;12(1):57-61. doi: 10.1006/scbi.2001.0398. Semin Cancer Biol. 2002. PMID: 11926413 Review. - HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?
Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. Rouas-Freiss N, et al. Cancer Res. 2005 Nov 15;65(22):10139-44. doi: 10.1158/0008-5472.CAN-05-0097. Cancer Res. 2005. PMID: 16287995 - Prognostic impact of anticancer immune responses: an introduction.
Pagés F, Kroemer G. Pagés F, et al. Semin Immunopathol. 2011 Jul;33(4):317-9. doi: 10.1007/s00281-011-0278-4. Epub 2011 May 28. Semin Immunopathol. 2011. PMID: 21626162 Review.
Cited by
- T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
Palecki J, Bhasin A, Bernstein A, Mille PJ, Tester WJ, Kelly WK, Zarrabi KK. Palecki J, et al. Cancer Biol Ther. 2024 Dec 31;25(1):2356820. doi: 10.1080/15384047.2024.2356820. Epub 2024 May 27. Cancer Biol Ther. 2024. PMID: 38801069 Free PMC article. Review. - Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.
Kostecki KL, Iida M, Crossman BE, Salgia R, Harari PM, Bruce JY, Wheeler DL. Kostecki KL, et al. Cancers (Basel). 2024 Jan 11;16(2):312. doi: 10.3390/cancers16020312. Cancers (Basel). 2024. PMID: 38254801 Free PMC article. Review. - Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway.
Luo X, Qiu Y, Fitzsimonds ZR, Wang Q, Chen Q, Lei YL. Luo X, et al. Oncogene. 2024 Feb;43(6):388-394. doi: 10.1038/s41388-023-02912-2. Epub 2024 Jan 4. Oncogene. 2024. PMID: 38177410 Review. - Contribution of natural killer cells in innate immunity against colorectal cancer.
Ghazvinian Z, Abdolahi S, Tokhanbigli S, Tarzemani S, Piccin A, Reza Zali M, Verdi J, Baghaei K. Ghazvinian Z, et al. Front Oncol. 2023 Jan 4;12:1077053. doi: 10.3389/fonc.2022.1077053. eCollection 2022. Front Oncol. 2023. PMID: 36686835 Free PMC article. Review. - Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
Han SH, Kim M, Chung YR, Woo JW, Choi HY, Park SY. Han SH, et al. Sci Rep. 2022 Nov 27;12(1):20367. doi: 10.1038/s41598-022-24890-3. Sci Rep. 2022. PMID: 36437379 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials